Drug Type Bispecific antibody |
Synonyms- |
Target |
Action antagonists |
Mechanism CCR4 antagonists(C-C chemokine receptor type 4 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | China | 21 Dec 2025 | |
| Stomach Cancer | Preclinical | China | 21 Dec 2025 |






